Alpha Cognition (ACOG) said Tuesday it has commercially launched Zunveyl for the treatment of mild to moderate Alzheimer's disease.
The company said the official commercial launch provides patients with access to 5 mg, 10 mg and 15 mg doses of the treatment through a prescription.
Shares of Alpha Cognition were more than 13% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.